GI cancers. This not only highlighted the heterogeneity in tumours of each primary anatomical site, it also identified novel therapeutic targets in distinct molecular subgroups and might improve the yield of clinical success. Molecular characteristics of tumours and their interaction with tumour microenvironment would further impact on development of combination therapy, including immunotherapy. Currently immune checkpoint blockade attracts the most intense research and the successful integration of these novel agents in GI cancers in the treatment paradigm requires an in-depth understanding of the diverse immune environment of these cancers.
INTRODUCTION
Cancers of gastrointestinal (GI) tract are among the most deadly malignancies with a high mortality to incidence ratio. Oesophago-gastric (OG), pancreatic, liver and colorectal (CRC) cancers account for more than 2,894,000 deaths per annum (1) .
Whereas serial incremental survival benefits have been made with cytotoxic chemotherapy with metastatic OG and colorectal cancers, a plateau of achievement has been reached. Applying modern integrative genomic technology, distinct molecular subgroups have been identified in GI cancers. This not only highlighted the heterogeneity in tumours of each primary anatomical site, it also identified novel therapeutic targets in distinct molecular subgroups and might improve the yield of (2) . This review focuses on the current and future approach of immunotherapy and its interface with the recent genomic data from GI cancers.
OESOPHAGO-GASTRIC CANCER
There have been several large scale research efforts to ascertain molecular subgrouping for gastric cancer. Notably the Cancer Genome Atlas (TCGA) identified four groups -Epstein Barr Virus (EBV) infected (9%), Microsatellite Instability (MSI 22%). Genomically Stability (GS 20%) and Chromosomal Instability (CIN 50%) (3).
The Asian Cancer Research Group (ACRG) also described 4 subgroups -MSI (22.7%), Microsatellite Stable (MSS)/ epithelial-to-mesenchymal transition (EMT 15.3%), MSS/TP53 positive (26.3%) and MSS/TP53 negative (35.7%) (4) . However of note the four subgroups described by the TCGA did not carry any prognostic effect, although this might be partly due to the tumour samples deriving from operable OG cancers with limited follow-up (3) . Furthermore, several molecular aberrations overlapped between different subgroups and thus these might not be completely distinct subgroups. For example PIK3CA mutations were frequently observed in the EBV subgroup, but were also found, albeit less frequently, in the MSI, GS and CIN subgroups. In contrast the four subgroups identified by the ACRG did have statistically significant survival differences (4). This prognostic difference between TCGA and ACRG was not necessarily related to the limited follow-up of the TCGA.
In addition, the semi-supervised analysis used by the ACRG with the incorporation of clinical characteristics might have contributed to this difference (3, 4) . Within the EBV-infected and MSI gastric cancer described in the TCGA, there were significantly higher expression of PD-L1 in both the tumour cells and immune cells compared to other subgroups (5, 6) . Furthermore interferon-γ gene set enrichment was also more frequently seen in the EBV-infected and MSI subgroups, although there was no association between interferon-γ signature and total number of mutations (5) . These subgroups might be particularly sensitive to PD-L1 blockade and of enhanced 6 relevance especially MSI gastric tumours might have a negative prognostic impact when treated with cytotoxic chemotherapy (7).
The initial enthusiasm in targeting PD-L1 in gastric adenocarcinoma came from the results of pembrolizumab in PD-L1 positive gastric cancer in the KEYNOTE-012 study (8) . In this study, patients from both Asian and non-Asian countries were enrolled. Forty per cent of screened population were found to be PD-L1 positive in a relatively heavily pre-treated patient population. An objective response rate (ORR) of 22% on central review and durable responses were seen with median duration of responses of 40 weeks. Six-month progression free survival (PFS) rate was 26% and impressively the median overall survival (OS) was 11.4 months with 12-month OS rate of 42%. Based on these, several randomised controlled trials (RCTs) have been/are being performed. Table 1 shows selected on-going randomised studies evaluating PD-(L)1 antibodies in GI cancers. In the second line KETNOTE-061 RCT, patients were not initially pre-selected for tumour PD-L1 expression, but PD-L1 positive patients were enriched at a latter part of the study. In the first line KEYNOTE-062 study, only patients with PD-L1 positive OG cancer are being recruited as this 3-arm RCT has a pembrolizumab alone treatment arm without any cytotoxic chemotherapy and data from KEYNOTE-012 were on PD-L1 positive gastric cancer alone.
Nivolumab has also been evaluated in a number of studies in gastric cancer. In the CHECKMATE 032 study, both nivolumab monotherapy and the combination of nivolumab plus ipilimumab were tested in gastric cancer patients. The combined PD-L1 and CTLA-4 targeting were first found to be valuable in malignant melanoma (9) , but more recently in other tumours such as small cell lung cancer (10) . CHECKMATE 032 gastric cohort recruited 160 gastric cancer patients who were allocated non-randomly to nivolumab (3mg/kg) monotherapy (n=59) and two dose schedules of nivolumab plus ipilimumab -nivolumab 1mg/kg and ipilimumab 3mg/kg (nivo 1 ipi 3; n=49) or nivolumab 3mg/kg + ipilimumab 1mg/kg (nivo 3 ipi 1; n=52) (11) . Similar to KEYNOTE-012, a heavily pre-treated patient population was recruited with 79% of patients had had ≥2 prior therapy. However unlike KETNOTE-012, patients were enrolled irrespective of PD-L1 expression status and all patients were of Western population. The ORR was 14% (nivo alone), 26% (nivo 1, ipi 3) and 10% (nivo 3, ipi1). The median duration of response was 7.1 months, 5.6 months and not reached respectively. Six-month PFS was 18%, 24% and 9% and 12 month OS was 36%, 34% and not available respectively. There was some correlation between ORR and PD-L1 expression for nivo alone, but less so with the combination of nivo and ipi similar to the observation in malignant melanoma (9, 11) .
Most recently a phase III placebo-controlled RCT was reported for nivolumab in third or subsequent line therapy. The ONO12 (ATTRACTION-2) study only recruited patients in Korea, Japan and China and thus consisted entirely of Asian population (12) . In this large study, 493 patients were randomised in a 2:1 fashion to nivolumab Avelumab, an anti-PD-L1 antibody, had been evaluated in a phase IB expanded cohort JAVELIN study in two different settings -maintenance post first line therapy and second line treatment (14) . In the second line setting, ORR was similar to nivolumab and pembrolizumab. Maintenance setting has so far not been explored by other PD-1 antibodies and forms the current registration strategy for avelumab in gastric cancer (Table 1) .
When one interrogated the integrated molecular description of gastric cancer in the TCGA, both JAK2/PD-L1/2 and VEGF A were altered in the CIN subgroup.
Targeting angiogenesis is now an established treatment options in gastric cancer (15, (Table 1 ).
There are a number of adaptive designed phase II studies either recruiting or being This subgroup had worse survival after relapse. For CMS 4 mesenchymal, there was stromal infiltration, TGF-β activation and angiogenesis. This subgroup had worse relapse-free and overall survival.
The immune landscape of these CMS had also been explored (27). CMS 1 and 4 had high expression of lymphoid as well as myeloid cell-specific genes, thus exhibiting a strong immune and inflammatory contexture. However, the poor prognostic CMS 4 differed from CMS1 with higher expression of endothelial cell and fibroblast genes.
In addition, functional relevant immune genes were also up-regulated in CMS 1 and CMS 4. CMS1 exhibited a high expression of genes coding for T-cell-attracting chemokines or involved in formation of tumour adjacent tertiary lymphoid structures, all associated with good prognosis in CRC. In contrast CM4 exhibited high expression of myeloid chemokine, angiogenic factors and immune-suppressive molecules (27). CMS2 and CMS3 might potentially be "immune deserts" consisting up to 50% of CRC cases whereas CMS1 and CMS 4 resembled more of "immune paradise" although CMS 4 also had inflammatory and angiogenic components ( Figure   1 ).
In the early development of anti-PD (L)1 antibodies, only marginal if any benefit was seen in metastatic CRC (mCRC). Much more encouraging efficacy was seen in a small subgroup of patients with mismatch repair (MMR) deficient mCRC. This subgroup only constituted ∼4-5% of all patients with mCRC. ORR of 62% was reported in 13 patients with MMR-deficient CRC using pembrolizumab whereas no response was observed in 25 patients with MMR-proficient CRC (28). In this study, 85% of patients with MMR deficiency were of Lynch Syndrome families.
Preliminary PFS and OS were all superior in the MMR deficient compared to MMR proficient patients (p=0.001 and p=0.03 respectively) when treated with pembrolizumab (28). In an updated analysis, a total of 53 patients (28 MMR deficient and 25 MMR proficient) were treated. ORR was 50% for MMR deficient CRC and 0% for MMR proficient CRC, respectively. For MMR deficient CRC, the PFS rates was 61% at 24 months and the OS rate was 66% at 24 months (29) . The number of somatic mutations was significantly higher in the MMR-deficient tumours compared to MMR proficient and this correlated with objective response (28). Mutation rate and neoantigen load might contribute to sensitivity to anti-PD-1 antibodies (30, 31), although this might not be an universal phenomenon in GI cancers.
A further study was recently reported evaluating nivolumab ± ipilimumab for MMR deficient mCRC (32, 33) . Larger number of patients were recruited in this study The first generation TLR-9 agonist developed was a CpG oligodeoxynucleotides (CpG-ODN) called PF3512676. Unfortunately when added to standard chemotherapy in non-small cell lung cancer, no survival benefit was seen (44, 45). The second generation TLR-9 agonist also halted development due to toxicity and lack of efficacy. The next generation TLR-9 agonist, lefitolimod (MGN 1703) underwent further structural changes which might improve efficacy and safety. Lefitolimod has been found to be much more potent than CpG-ODN with evidence of immune activation in heavily pre-treated patients with solid tumours and mCRC in particular.
Both innate and adaptive immune responses were seen in vivo (41). Lefitolimod was tested in a small randomised placebo controlled trial as maintenance therapy. Patients who had completed first line therapy with oxaliplatin or irinotecan/ fluoropyrimidine ± bevzcizumab were randomly allocated to lefitolimod or placebo (46). There was a trend towards better PFS with lefitolimod from randomisation and statistically significant better PFS from start of induction therapy. In addition, the greatest benefit of lefitolimod appeared to be in patients with relatively low tumour burden.
Therefore IMPALA, the phase III RCT of lefitolimod, is recruiting 540 mCRC patients with at least partial responses to first line therapy as maintenance therapy.
The addition of pembrolizumab to TLR-4 agonist is also being evaluated in other tumours such as follicular lymphoma. A phase 1b/2 study is designed to evaluate intratumoural G100 (TLR-4 agonist) plus local radiation and pembrolizumab versus G100 plus local radiation alone in patients with follicular lymphoma (NCT: 02501473).
As prognostication, the Immunoscore has gained much recent attention. Taking PD-L1 positive PDAC had less favourable prognosis although expression was sparse (53) . In a phase II study of ipilimumab in metastatic pancreatic cancer, no objective response was observed out of 23 patients although 1 patient had immune related response (54). In another study of ipilimumab with or without GVAX, a vaccine based on allogeneic pancreatic tumour cells genetically modified to produce GM-CSF, again no responses was seen although decrease in CA19-9 marker level was observed when GVAX was added (55) . Furthermore in a phase 1 study of PD-L1
antibody, there were no responses seen out of 14 patients with PDAC (56). In MMR deficient pancreatic cancer, objective responses have been seen with pembrolizumab but patient number was extremely limited (57).
The largest study evaluating immunotherapy approach in advanced PDAC was the TELOVAC study (58) . GV1001, a human telomerase reverse transcriptase catalytic subunit (hTERT) class II peptide vaccine was given either sequentially after chemotherapy or concomitantly with chemotherapy. Gemcitabine plus capecitabine was given both as control arm and also as chemotherapy with GV1001 in the experimental arms. TELOVAC was probably the largest RCT ever conducted in advanced PDAC with 1,002 patients randomised to these three arms. Unfortunately no survival benefit was seen with this immunotherapeutic approach (58).
The "immune desert" of pancreatic cancer represented a major therapeutic challenge. There is paucity of clinical data in the use of anti-PD-(L)1 antibody in advanced BTC.
Pembrolizumab was tested in a multi-cohort phase IB KEYNOTE -028 (65) . Only patients with PD-L1 positive tumours were recruited. Of the screened advanced BTC population, 42% were PD-L1 positive. Twenty-four patients were recruited and ORR of 17% was observed (65) . In the aforementioned phase 1 study evaluating pembrolizumab plus ramucirumab in gastric cancer patients, there was a separate cohort of advanced BTC patients which have completed recruitment, but no results
are available yet.
Hepatocellular carcinoma has distinct immune environment which might represent potential "immune paradise" for checkpoint inhibition. However a separate review article will focus on this particular subject. 
CONCLUSIONS

